TSLA: Tesla Robotaxi Push Could Be a $1 Trillion Game-Changer
June 20 - Tesla (NASDAQ:TSLA) is set to launch its robotaxi operations in Austin this Sunday, with about 20 Model Y vehicles operating in a designated area, Wedbush mentioned in a Friday note.
The firm called the move a key milestone that could define Tesla's next phase, estimating the autonomous unit alone could eventually add $1 trillion to the electric carmaker's valuation.
Wedbush maintained its Outperform rating and $500 price target, citing Tesla's global reach and progress in artificial intelligence and driverless technology.
The firm expects Tesla to scale the service to roughly 25 U.S. cities within a year and sees potential policy support ahead. Analysts said a Trump presidency could accelerate regulatory clearance for full self-driving systems.
Tesla plans to begin production of its dedicated robotaxi model, the Cybercab, sometime next year, the note added.
Wedbush believes Tesla's roadmap on autonomy and robotics will unfold gradually, saying, Rome wasn't built in a day. In a bull case, the firm sees Tesla reaching a $2 trillion market cap by the end of 2026.
This article first appeared on GuruFocus.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 minutes ago
- Yahoo
Is NRG Energy Stock Outperforming the S&P 500?
Houston, Texas-based NRG Energy, Inc. (NRG) is an energy and home services company in the United States and Canada. With a market cap of $29.8 billion, the company operates through Texas, East, West/Services/Other, Vivint Smart Home, and Corporate Activities segments. Companies worth $10 billion or more are generally described as 'large-cap stocks', and NRG Energy fits this criterion perfectly. The company operates a diverse portfolio of electricity-generating assets and provides energy solutions to residential, commercial, and industrial customers. It focuses on innovation and sustainability, offering retail electricity plans, energy management tools, and decarbonization services. 2 Outstanding Stocks Under $50 to Buy and Hold Now Nvidia's Bringing Sovereign AI to Germany. Should You Buy NVDA Stock Here? A $1 Billion Reason to Buy MicroStrategy Stock Here Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered right when you need the info most. Subscribe today! NRG Energy currently trades nearly 6% below its all-time high of $162.33 recorded on Jun. 3. NRG's stock has gained 61.2% in the past three months, notably surpassing the S&P 500 Index's ($SPX) 5.4% increase. In the longer term, NRG has surged 69.2% on a YTD basis, whereas SPX has risen 1.7%. Moreover, shares of NRG Energy soared 91% over the past 52 weeks, significantly outperforming the SPX's 9% return over the same time frame. The stock has been trading above its 50-day moving average since late April, and despite some fluctuations, it has also remained above its 200-day average since last year, underscoring its bullish trend. NRG Energy's stock soared 26.2% following the release of its better-than-expected Q1 2025 results on May 12. The company reported $8.6 billion in revenues, up 15.6% year-over-year, significantly exceeding consensus estimates. Meanwhile, its adjusted EPS surged 83.6% from the year-ago quarter to $2.68, beating analyst expectations by 45.6%. Compared to its rival, Vistra Corp. (VST) has lagged behind the NRG stock on a YTD basis, gaining 31.4%. Although VST stock has climbed 106.8% over the past 52 weeks, outpacing NRG stock. Among the 11 analysts covering the NRG stock, the consensus rating is a 'Strong Buy.' Its mean price target of $160 suggests a modest 4.8% upside potential from current price levels. On the date of publication, Aditya Sarawgi did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Sign in to access your portfolio
Yahoo
13 minutes ago
- Yahoo
I'm a Car Expert: 4 Hybrid Vehicles I'd Consider Buying and Why They're Worth It
Hybrid cars are becoming more popular. But how can car buyers know which ones are worth the money? Luckily, GOBankingRates consulted experts to find out. Check Out: Learn More: For the following list of hybrid vehicles worth buying, cars were compared on reliability, maintenance ease, actual fuel economy improvements and total value at the price point. Also see five hybrid vehicles that aren't worth the money. 2025 starting MSRP: $23,825 The Corolla has dominated compact car sales worldwide for decades, and the hybrid version only improves on the original. 'With fuel efficiency up to 50 miles per gallon, the Corolla hybrid combines dependable operation, outstanding fuel efficiency and simple design,' said Alan Gelfand, who has three decades' worth of experience running a mechanic shop at German Car Depot. He's not the only auto expert who raves about the Corolla hybrid. Alex Black, owner of vehicle research platform EpicVIN, also pointed to it as the best value option. 'It is dead simple, inexpensive to operate, as solid as they come and simple to replace parts. It may not be glamorous, but if you need a car that lasts and economizes, this one is the best,' he said. Read Next: 2025 starting MSRP: $28,295 The larger Accord achieves nearly the same fuel efficiency at up to 48 mpg, with a fun-to-drive 204 horsepower. 'The Accord Hybrid delivers a spacious interior and smooth driving dynamics that match entry-level luxury cars,' Gelfand said. 2025 starting MSRP: $44,735 Want luxury looks and features without compromising on reliability? Toyota brings its signature dependability to its upscale Lexus line. Black absolutely loves the ES 300h. 'It's essentially a Camry Hybrid in a business suit. Smoothest ride going, quiet interior and Lexus-quality construction,' he said. Gelfand added that the ES 300h can survive for 200,000 miles and beyond. 'The ES 300h reaches 43-45 mpg on average, and its hybrid parts demonstrate exceptional reliability,' he said. 2025 RAV4 starting MSRP: $32,300 2025 Prime starting MSRP: $44,265 Toyota makes both a traditional hybrid RAV4 and a plug-in hybrid Prime model that runs on an all-electric engine with a gas backup for road trips and quick fill-ups. The hybrid version achieves around 38 mpg, and the Prime version has a battery range of 42 electric-only miles. 'Maintenance of these models remains uncomplicated for users,' Gelfand said. 'The eCVT system operating throughout Toyota hybrid models eliminates traditional transmission issues.' More From GOBankingRates 3 Luxury SUVs That Will Have Massive Price Drops in Summer 2025 I'm a Retired Boomer: 6 Bills I Canceled This Year That Were a Waste of Money 10 Unreliable SUVs To Stay Away From Buying This article originally appeared on I'm a Car Expert: 4 Hybrid Vehicles I'd Consider Buying and Why They're Worth It
Yahoo
14 minutes ago
- Yahoo
Elevance Health (NYSE:ELV) shareholders have earned a 9.3% CAGR over the last five years
It hasn't been the best quarter for Elevance Health, Inc. (NYSE:ELV) shareholders, since the share price has fallen 12% in that time. On the bright side the share price is up over the last half decade. However we are not very impressed because the share price is only up 46%, less than the market return of 104%. While the long term returns are impressive, we do have some sympathy for those who bought more recently, given the 30% drop, in the last year. So let's investigate and see if the longer term performance of the company has been in line with the underlying business' progress. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. In his essay The Superinvestors of Graham-and-Doddsville Warren Buffett described how share prices do not always rationally reflect the value of a business. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price. Over half a decade, Elevance Health managed to grow its earnings per share at 6.9% a year. This EPS growth is reasonably close to the 8% average annual increase in the share price. That suggests that the market sentiment around the company hasn't changed much over that time. Rather, the share price has approximately tracked EPS growth. The company's earnings per share (over time) is depicted in the image below (click to see the exact numbers). This free interactive report on Elevance Health's earnings, revenue and cash flow is a great place to start, if you want to investigate the stock further. It is important to consider the total shareholder return, as well as the share price return, for any given stock. Whereas the share price return only reflects the change in the share price, the TSR includes the value of dividends (assuming they were reinvested) and the benefit of any discounted capital raising or spin-off. So for companies that pay a generous dividend, the TSR is often a lot higher than the share price return. In the case of Elevance Health, it has a TSR of 56% for the last 5 years. That exceeds its share price return that we previously mentioned. The dividends paid by the company have thusly boosted the total shareholder return. Elevance Health shareholders are down 29% for the year (even including dividends), but the market itself is up 12%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. Longer term investors wouldn't be so upset, since they would have made 9%, each year, over five years. If the fundamental data continues to indicate long term sustainable growth, the current sell-off could be an opportunity worth considering. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. For instance, we've identified 1 warning sign for Elevance Health that you should be aware of. Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
